Tris Pharma, an emerging specialty pharmaceutical company, announced the US grant of its core technology patent for its OralXR+™ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes.
"This patent grant further validates Tris' breakthrough in commercializing modified release formulation involving unique dosage forms such as a 24-hour ER liquid suspension. The patent covers our unique, high tensile, aqueous coating compositions and combined with our patent-pending/trade-secret manufacturing process and special design apparatus provides for an efficient and scalable manufacturing capabilities. This has resulted in launch of several new, first-in-the-category products that were heretofore not capable of being developed," said Ketan Mehta, President and CEO of Tris Pharma.
Revolutionising organoid manufacturing: Monmouth Scientific Class 2 Biological Safety Cabinets enhance sterility and efficiency at Molecular Devices' new Life Science facility.